Side Effects of Biological Treatment in Rheumatic Patients
Coffler, Karin |
Recenzentas / Reviewer | |
Komisijos pirmininkas / Committee Chairman | |
Komisijos narys / Committee Member | |
Komisijos narys / Committee Member | |
Komisijos narys / Committee Member |
The aim of this research was to investigate the side effects of intravenous biological drugs used for treatment of rheumatic diseases in the Rheumatology Department of Kaunas Clinics. Objectives: 1.Create a questionnaire to collect information on IV therapy and reported side effects. 2.Analyze the short- and long-term side effects of patients who are treated in the department. 3.Compare the distribution of side effects between different drugs. 4.Prepare practical recommendations for the biological treatment of rheumatic patients. Methodology: goal-specific questionnaire for collecting, analyzing, interpreting data. Following completion of the statistical analysis of the results received, it was determined that almost all patients find IV biological therapy useful and do not cease it, and the majority of those that receive it have no side effects. Most side effects have been recorded with the drugs Infliximab and Belimumab. The most common side effects of IV biological therapy were shown to include weakness, dizziness, unusual fatigue, low energy, urinary tract infection, sudden cough, chest pain, and fever. It is recommended that a responsible resident doctor or medical nurse allow the patient to be aware of the optionally described adverse effects after the treatment is delivered. Ways to behave in such cases should be offered.
Pagrindinis atlikto tyrimo tikslas – ištirti Kauno klinikų Reumatologijos skyriuje intraveninių biologinių vaistų, vartojamų reumatinėms ligoms gydyti, šalutinį poveikį. Uždaviniai: 1. Sukurkite klausimyną, kad surinktumėte informaciją apie IV gydymą ir praneštus šalutinius poveikius. 2.Išanalizuoti trumpalaikį ir ilgalaikį šalutinį poveikį pacientams, kurie gydomi skyriuje. 3.Palyginkite šalutinio poveikio pasiskirstymą tarp skirtingų vaistų. 4.Parengti praktines reumatinių ligonių biologinio gydymo rekomendacijas. Remiantis rezultatais, padarytos išvados ir praktinės rekomendacijos.